Lv3
270 积分 2023-03-28 加入
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
1个月前
已完结
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
1个月前
已完结
An open‐label, prospective trial to evaluate the efficacy and safety of ixazomib in combination with cyclophosphamide and dexamethasone in patients with newly diagnosed POEMS syndrome
10个月前
已完结
Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study
1年前
已完结
A real‐life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis
1年前
已完结
Bone marrow tracer uptake pattern of PET-CT in multiple myeloma: image interpretation and prognostic value
1年前
已完结
Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis
1年前
已完结
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
1年前
已完结
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
1年前
已完结
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
1年前
已完结
皖公网安备34019202002308
